Datao Liu, Mabwell Therapeutics CEO
January 20, 2023 08:42 AM ESTUpdated 09:28 AM
Deals

Disc Med­i­cine pays $10M up­front for mon­o­clon­al an­ti­body for rare blood dis­or­der, can­cer

Katherine Lewin

News Reporter

Hema­tol­ogy-fo­cused Disc Med­i­cine has agreed to pay a $10 mil­lion down pay­ment to Mab­well Ther­a­peu­tics to de­vel­op and com­mer­cial­ize a port­fo­lio …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times